Dr. Rebecca Auer (@auer_r on twitter: https://twitter.com/auer_r?lang=en) is a Surgical Oncologist and translational researcher studying the impact of surgery on the immune system and subsequent cancer recurrence. In her laboratory the focus is to develop innovative cancer therapeutics that can be administered during the perioperative period and to translate these therapies to the clinic. With three active clinical studies of perioperative cancer therapies, Dr. Auer aims to improve cancer outcomes for all patients who undergo invasive cancer surgeries.Dr. Auer talks about her training pathway, being a surgeon-scientist, developing a COVID19 vaccine, her work on vaccines and cancer, and her tips for "work-life harmony".Links:1. Rebecca Auer bio: http://www.ohri.ca/profile/rauer2. Dr. Auer lab page: https://www.auerlab.com/3. Are morbidity and mortality conferences becoming a lost art?: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440886/4. Morbidity and mortality conferences in general surgery: a narrative systematic review: http://canjsurg.ca/63-3-e211/5. Perioperative Influenza Vaccination Reduces Postoperative Metastatic Disease by Reversing Surgery-Induced Dysfunction in Natural Killer Cells: https://clincancerres.aacrjournals.org/content/19/18/5104.long6. Killers 2.0: NK cell therapies at the forefront of cancer control: https://www.jci.org/articles/view/129338

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related